Amogen Pharma is India's leading recombinant peptide and biosimilar company, developing and manufacturing GLP-1 APIs including semaglutide and liraglutide via proprietary Saccharomyces cerevisiae fermentation technology. Founded in 2020 and headquartered in Hyderabad, India, Amogen operates Plant 1 — India's largest dedicated GLP-1 API facility with 980 Kg API capacity. Our pipeline includes semaglutide (Phase 1, Q4 2026), liraglutide, tirzepatide, insulin degludec, insulin aspart and Insulin Degludec + Liraglutide — covering a cumulative market of $80B+. We partner globally for API supply, FDF licensing and long-term commercial agreements across India, GCC, ASEAN, LATAM,Canada, EU and North America.
| Website | https://www.amogenpharma.com |
| Employees | 39 (17 on RocketReach) |
| Founded | 2020 |
| Industry | Biotechnology Research |
| Keywords | Peptide Manufacturing, Quality Pharmaceuticals, Affordable Medications, Pharmaceutical Peptides, Biopharmaceutical Manufacturing, Scientific Breakthroughs, High Quality Peptides, Drug Development, Pharmaceutical Production, Peptide Synthesis, Peptide Therapeutics, Pharmaceutical Research, Drug Manufacturing, Medicine Development, Generic Drugs, Pharmaceutical Ingredients, Biotechnology |
Looking for a particular Amogen Pharma employee's phone or email?
Manpreet Singh is the President Business Development of Amogen Pharma.
17 people are employed at Amogen Pharma.
Amogen Pharma is based in Hyderabad, Telangana.